Long	long	O	O	O	O
term	term	O	O	O	O
hormone	hormone	O	O	O	O
therapy	therapy	O	O	O	O
for	for	O	O	O	O
perimenopausal	perimenopausal	O	O	O	O
and	and	O	O	O	O
postmenopausal	postmenopausal	O	O	O	O
women	women	O	O	O	O
.	.	O	O	O	O

BACKGROUND	background	O	O	O	O
:	:	O	O	O	O
Hormone	hormone	O	O	O	O
therapy	therapy	O	O	O	O
(	(	O	O	O	O
HT	ht	O	O	OTHERS	I
)	)	O	O	O	O
is	is	O	O	O	O
widely	widely	O	O	O	O
used	used	O	O	O	O
for	for	O	O	O	O
controlling	controlling	O	O	O	O
menopausal	menopausal	O	O	OTHERS	I
symptoms	symptoms	O	O	OTHERS	I
and	and	O	O	O	O
has	has	O	O	O	O
also	also	O	O	O	O
been	been	O	O	O	O
used	used	O	O	O	O
for	for	O	O	O	O
the	the	O	O	O	O
management	management	O	O	O	O
and	and	O	O	O	O
prevention	prevention	O	O	O	O
of	of	O	O	O	O
cardiovascular	cardiovascular	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
,	,	O	O	O	O
osteoporosis	osteoporosis	O	DISEASE	OTHERS	I
and	and	O	O	O	O
dementia	dementia	O	DISEASE	OTHERS	I
in	in	O	O	O	O
older	older	O	O	O	O
women	women	O	O	O	O
.	.	O	O	O	O

This	this	O	O	O	O
is	is	O	O	O	O
an	an	O	O	O	O
updated	updated	O	O	O	O
version	version	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
original	original	O	O	O	O
Cochrane	cochrane	O	O	O	O
review	review	O	O	O	O
first	first	O	O	O	O
published	published	O	O	O	O
in	in	O	O	O	O
2005	2005	O	O	O	O
.	.	O	O	O	O

OBJECTIVES	objectives	O	O	O	O
:	:	O	O	O	O
To	to	O	O	O	O
assess	assess	O	O	O	O
the	the	O	O	O	O
effect	effect	O	O	O	O
of	of	O	O	O	O
long-term	long-term	O	O	O	O
HT	ht	O	O	OTHERS	I
on	on	O	O	O	O
mortality	mortality	O	O	O	O
,	,	O	O	O	O
cardiovascular	cardiovascular	O	O	O	O
outcomes	outcomes	O	O	O	O
,	,	O	O	O	O
cancer	cancer	O	DISEASE	OTHERS	I
,	,	O	O	O	O
gallbladder	gallbladder	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
,	,	O	O	O	O
cognition	cognition	O	O	O	O
,	,	O	O	O	O
fractures	fractures	O	DISEASE	OTHERS	I
and	and	O	O	O	O
quality	quality	O	O	O	O
of	of	O	O	O	O
life	life	O	O	O	O
.	.	O	O	O	O

SEARCH	search	O	O	O	O
STRATEGY	strategy	O	O	O	O
:	:	O	O	O	O
We	we	O	O	O	O
searched	searched	O	O	O	O
the	the	O	O	O	O
following	following	O	O	O	O
databases	databases	O	O	O	O
to	to	O	O	O	O
November	november	O	O	O	O
2007	2007	O	O	O	O
:	:	O	O	O	O
Trials	trials	O	O	O	O
Register	register	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
Cochrane	cochrane	O	O	O	O
Menstrual	menstrual	O	O	OTHERS	I
Disorders	disorders	O	O	OTHERS	I
and	and	O	O	O	O
Subfertility	subfertility	O	O	O	O
Group	group	O	O	O	O
,	,	O	O	O	O
Cochrane	cochrane	O	O	O	O
Central	central	O	O	O	O
Register	register	O	O	O	O
of	of	O	O	O	O
Controlled	controlled	O	O	O	O
Trials	trials	O	O	O	O
,	,	O	O	O	O
MEDLINE	medline	O	O	O	O
,	,	O	O	O	O
EMBASE	embase	O	O	O	O
,	,	O	O	O	O
Biological	biological	O	O	O	O
Abstracts	abstracts	O	O	O	O
.	.	O	O	O	O

Also	also	O	O	O	O
relevant	relevant	O	O	O	O
non-indexed	non-indexed	O	O	O	O
journals	journals	O	O	O	O
and	and	O	O	O	O
conference	conference	O	O	O	O
abstracts	abstracts	O	O	O	O
.	.	O	O	O	O

SELECTION	selection	O	O	O	O
CRITERIA	criteria	O	O	O	O
:	:	O	O	O	O
Randomised	randomised	O	O	O	O
double-blind	double-blind	O	O	O	O
trials	trials	O	O	O	O
of	of	O	O	O	O
HT	ht	O	O	OTHERS	I
versus	versus	O	O	O	O
placebo	placebo	O	O	O	O
,	,	O	O	O	O
taken	taken	O	O	O	O
for	for	O	O	O	O
at	at	O	O	O	O
least	least	O	O	O	O
one	one	O	O	O	O
year	year	O	O	O	O
by	by	O	O	O	O
perimenopausal	perimenopausal	O	O	O	O
or	or	O	O	O	O
postmenopausal	postmenopausal	O	O	O	O
women	women	O	O	O	O
.	.	O	O	O	O

HT	ht	O	O	OTHERS	I
included	included	O	O	O	O
oestrogens	oestrogens	O	O	OTHERS	I
,	,	O	O	O	O
with	with	O	O	O	O
or	or	O	O	O	O
without	without	O	O	O	O
progestogens	progestogens	O	O	OTHERS	I
,	,	O	O	O	O
via	via	O	O	O	O
oral	oral	O	O	O	O
,	,	O	O	O	O
transdermal	transdermal	O	O	O	O
,	,	O	O	O	O
subcutaneous	subcutaneous	O	O	O	O
or	or	O	O	O	O
transnasal	transnasal	O	O	O	O
routes	routes	O	O	O	O
.	.	O	O	O	O

DATA	data	O	O	O	O
COLLECTION	collection	O	O	O	O
AND	and	O	O	O	O
ANALYSIS	analysis	O	O	O	O
:	:	O	O	O	O
Two	two	O	O	O	O
authors	authors	O	O	O	O
independently	independently	O	O	O	O
assessed	assessed	O	O	O	O
trial	trial	O	O	O	O
quality	quality	O	O	O	O
and	and	O	O	O	O
extracted	extracted	O	O	O	O
data	data	O	O	O	O
.	.	O	O	O	O

MAIN	main	O	O	O	O
RESULTS	results	O	O	O	O
:	:	O	O	O	O
Nineteen	nineteen	O	O	O	O
trials	trials	O	O	O	O
involving	involving	O	O	O	O
41,904	41,904	O	O	O	O
women	women	O	O	O	O
were	were	O	O	O	O
included	included	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
relatively	relatively	O	O	O	O
healthy	healthy	O	O	O	O
women	women	O	O	O	O
,	,	O	O	O	O
combined	combined	O	O	O	O
continuous	continuous	O	O	O	O
HT	ht	O	O	OTHERS	I
significantly	significantly	O	O	O	O
increased	increased	O	O	O	O
the	the	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
venous	venous	O	O	O	O
thrombo-embolism	thrombo-embolism	O	O	O	O
or	or	O	O	O	O
coronary	coronary	O	O	O	O
event	event	O	O	O	O
(	(	O	O	O	O
after	after	O	O	O	O
one	one	O	O	O	O
year	year	O	O	O	O
's	's	O	O	O	O
use	use	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
stroke	stroke	O	DISEASE	OTHERS	I
(	(	O	O	O	O
after	after	O	O	O	O
three	three	O	O	O	O
years	years	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
breast	breast	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
and	and	O	O	O	O
gallbladder	gallbladder	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Long-term	long-term	O	O	O	O
oestrogen-only	oestrogen-only	O	O	O	O
HT	ht	O	O	OTHERS	I
significantly	significantly	O	O	O	O
increased	increased	O	O	O	O
the	the	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
venous	venous	O	O	O	O
thrombo-embolism	thrombo-embolism	O	O	O	O
,	,	O	O	O	O
stroke	stroke	O	DISEASE	OTHERS	I
and	and	O	O	O	O
gallbladder	gallbladder	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
(	(	O	O	O	O
after	after	O	O	O	O
one	one	O	O	O	O
to	to	O	O	O	O
two	two	O	O	O	O
years	years	O	O	O	O
,	,	O	O	O	O
three	three	O	O	O	O
years	years	O	O	O	O
and	and	O	O	O	O
seven	seven	O	O	O	O
years	years	O	O	O	O
'	'	O	O	O	O
use	use	O	O	O	O
respectively	respectively	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
but	but	O	O	O	O
did	did	O	O	O	O
not	not	O	O	O	O
significantly	significantly	O	O	O	O
increase	increase	O	O	O	O
the	the	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
breast	breast	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
only	only	O	O	O	O
statistically	statistically	O	O	O	O
significant	significant	O	O	O	O
benefits	benefits	O	O	O	O
of	of	O	O	O	O
HT	ht	O	O	OTHERS	I
were	were	O	O	O	O
a	a	O	O	O	O
decreased	decreased	O	O	O	O
incidence	incidence	O	O	O	O
of	of	O	O	O	O
fractures	fractures	O	DISEASE	OTHERS	I
and	and	O	O	O	O
(	(	O	O	O	O
for	for	O	O	O	O
combined	combined	O	O	O	O
HT	ht	O	O	OTHERS	I
)	)	O	O	O	O
colon	colon	O	O	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
,	,	O	O	O	O
with	with	O	O	O	O
long-term	long-term	O	O	O	O
use	use	O	O	O	O
.	.	O	O	O	O

Among	among	O	O	O	O
women	women	O	O	O	O
aged	aged	O	O	O	O
over	over	O	O	O	O
65	65	O	O	O	O
who	who	O	O	O	O
were	were	O	O	O	O
relatively	relatively	O	O	O	O
healthy	healthy	O	O	O	O
(	(	O	O	O	O
i.e.	i.e.	O	O	O	O
generally	generally	O	O	O	O
fit	fit	O	O	O	O
,	,	O	O	O	O
without	without	O	O	O	O
overt	overt	O	O	O	O
disease	disease	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
taking	taking	O	O	O	O
continuous	continuous	O	O	O	O
combined	combined	O	O	O	O
HT	ht	O	O	OTHERS	I
,	,	O	O	O	O
there	there	O	O	O	O
was	was	O	O	O	O
a	a	O	O	O	O
statistically	statistically	O	O	O	O
significant	significant	O	O	O	O
increase	increase	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
incidence	incidence	O	O	O	O
of	of	O	O	O	O
dementia	dementia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Among	among	O	O	O	O
women	women	O	O	O	O
with	with	O	O	O	O
cardiovascular	cardiovascular	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
,	,	O	O	O	O
long-term	long-term	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
combined	combined	O	O	O	O
continuous	continuous	O	O	O	O
HT	ht	O	O	OTHERS	I
significantly	significantly	O	O	O	O
increased	increased	O	O	O	O
the	the	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
venous	venous	O	O	O	O
thrombo-embolism	thrombo-embolism	O	O	O	O
.	.	O	O	O	O

One	one	O	O	O	O
trial	trial	O	O	O	O
analysed	analysed	O	O	O	O
subgroups	subgroups	O	O	O	O
of	of	O	O	O	O
2839	2839	O	O	O	O
relatively	relatively	O	O	O	O
healthy	healthy	O	O	O	O
50	50	O	O	O	O
to	to	O	O	O	O
59	59	O	O	O	O
year	year	O	O	O	O
old	old	O	O	O	O
women	women	O	O	O	O
taking	taking	O	O	O	O
combined	combined	O	O	O	O
continuous	continuous	O	O	O	O
HT	ht	O	O	OTHERS	I
and	and	O	O	O	O
1637	1637	O	O	O	O
taking	taking	O	O	O	O
oestrogen-only	oestrogen-only	O	O	O	O
HT	ht	O	O	OTHERS	I
,	,	O	O	O	O
versus	versus	O	O	O	O
similar-sized	similar-sized	O	O	O	O
placebo	placebo	O	O	O	O
groups	groups	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
only	only	O	O	O	O
significantly	significantly	O	O	O	O
increased	increased	O	O	O	O
risk	risk	O	O	O	O
reported	reported	O	O	O	O
was	was	O	O	O	O
for	for	O	O	O	O
venous	venous	O	O	O	O
thrombo-embolism	thrombo-embolism	O	O	O	O
in	in	O	O	O	O
women	women	O	O	O	O
taking	taking	O	O	O	O
combined	combined	O	O	O	O
continuous	continuous	O	O	O	O
HT	ht	O	O	OTHERS	I
:	:	O	O	O	O
their	their	O	O	O	O
absolute	absolute	O	O	O	O
risk	risk	O	O	O	O
remained	remained	O	O	O	O
low	low	O	O	O	O
,	,	O	O	O	O
at	at	O	O	O	O
less	less	O	O	O	O
than	than	O	O	O	O
1/500	1/500	O	O	O	O
.	.	O	O	O	O

However	however	O	O	O	O
,	,	O	O	O	O
this	this	O	O	O	O
study	study	O	O	O	O
was	was	O	O	O	O
not	not	O	O	O	O
powered	powered	O	O	O	O
to	to	O	O	O	O
detect	detect	O	O	O	O
differences	differences	O	O	O	O
between	between	O	O	O	O
groups	groups	O	O	O	O
of	of	O	O	O	O
younger	younger	O	O	O	O
women	women	O	O	O	O
.	.	O	O	O	O

AUTHORS	authors	O	O	O	O
'	'	O	O	O	O
CONCLUSIONS	conclusions	O	O	O	O
:	:	O	O	O	O
HT	ht	O	O	OTHERS	I
is	is	O	O	O	O
not	not	O	O	O	O
indicated	indicated	O	O	O	O
for	for	O	O	O	O
the	the	O	O	O	O
routine	routine	O	O	O	O
management	management	O	O	O	O
of	of	O	O	O	O
chronic	chronic	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
.	.	O	O	O	O

We	we	O	O	O	O
need	need	O	O	O	O
more	more	O	O	O	O
evidence	evidence	O	O	O	O
on	on	O	O	O	O
the	the	O	O	O	O
safety	safety	O	O	O	O
of	of	O	O	O	O
HT	ht	O	O	OTHERS	I
for	for	O	O	O	O
menopausal	menopausal	O	O	O	O
symptom	symptom	O	O	O	O
control	control	O	O	O	O
,	,	O	O	O	O
though	though	O	O	O	O
short-term	short-term	O	O	O	O
use	use	O	O	O	O
appears	appears	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
relatively	relatively	O	O	O	O
safe	safe	O	O	O	O
for	for	O	O	O	O
healthy	healthy	O	O	O	O
younger	younger	O	O	O	O
women	women	O	O	O	O
.	.	O	O	O	O

